Answers are grounded in this paper and cite their sources.
Objective As the host's genetics influences immune response to HIV-1 and progression to AIDS, similar genetic factors could affect response to immunotherapy. Differential genes expression was evaluated in clinical trial, aimed at identifying a potential predictive marker for DC quality and, finally, for therapy responsiveness. Methods and Results DC used for immunotherapy revealed a clear difference of anti-HIV genes signature, so we classified DC into two groups (A-DC and B-DC). In A-DC a limited number of genes, including inflammasome-related genes ( IL1B, IL18 ), were modulated during monocytes-to-DC differentiation. A larger subset of anti-HIV genes (restriction factors, co-factors, apoptotic factors) was modulated in B-DC. This more “activated/exhausted” expression profile of B-DC apparently resulted from a more activated monocyte precursor. Conclusions These results suggest that the actual selection of HIV + individual for immunotherapy, based on clinical features, did not ensure the same DC product, and that less “activated/exhausted” DC could positively affect the outcome of immunotherapy.
No takes yet. Share an insight, caveat, or question.
Pontillo et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: